Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 7/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25090250 | 1.00 | PAOX (0.52) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL25453657 | 1.00 | PAOX (0.52) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL13311546 | 1.00 | PAOX (0.52) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL25453158 | 1.00 | PAOX (0.52) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL25453230 | 1.00 | PAOX (0.52) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL13662526 | 0.98 | PAOX (0.48) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL10125881 | 0.91 | ALDH1A1 (0.41) | PAOXMAPK1MEN1FAAHKMT2A | |
| SCHEMBL21297375 | 0.83 | PAOX (0.48) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL12902809 | 0.83 | CASP2 (0.47) | PAOXADRA1AMAPK1MEN1FAAH | |
| SCHEMBL24654362 | 0.83 | KDM4E (0.38) | PAOXMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | PAOX 3820/4885ADRA1A 3909/4885MAPK1 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.